Registration of Medicinal Products in Azerbaijan:
An Overview
Azerbaijan is one of the fastest-growing pharmaceutical markets in the South Caucasus, offering attractive opportunities for international pharmaceutical manufacturers seeking access to a population of over 10 million people. The country's healthcare system continues to evolve through the expansion of mandatory health insurance, increasing healthcare expenditure, and the introduction of regulatory reforms aimed at improving patient access to innovative therapies.
Before a medicinal product can be marketed in Azerbaijan, it must obtain a Marketing Authorization issued by the Ministry of Health. The registration process is coordinated through the Center of Analytics and Expertise (CAE), which evaluates the quality, safety, and efficacy of medicinal products.
Currently, pharmaceutical companies can access the Azerbaijani market through three registration pathways:
The Standard Registration Procedure involves a full scientific review of the registration dossier and is applicable to both innovative and generic medicines. The review process typically takes 8–12 months.
The Recognition Procedure, introduced to facilitate faster access to medicines, allows products approved by trusted regulatory authorities such as the EMA and FDA to undergo a simplified review process. This pathway significantly reduces registration timelines to approximately 2–3 months.
For orphan medicinal products, a dedicated listing mechanism may provide access to patients with rare diseases under specific regulatory conditions.
Following registration, companies must obtain price approval from the Tariff Council. This process generally requires an additional 1–2 months before commercial launch.
As a result, the overall timeline from submission to market entry is approximately:
Marketing Authorizations issued in Azerbaijan are valid for five years and must be renewed upon expiration.
Beyond registration, pharmaceutical companies may seek inclusion in publicly funded healthcare programs. Typically, reimbursement or public procurement discussions begin after a product has been available on the private market for at least one year.
Nexa Pharm provides comprehensive regulatory support for pharmaceutical companies entering the Azerbaijani market, including registration strategy, dossier preparation, regulatory submissions, lifecycle management, pricing support, and market access consulting.
With extensive experience supporting both multinational pharmaceutical companies and emerging biotech innovators, Nexa Pharm combines local regulatory expertise with international industry standards to help clients achieve efficient and compliant market entry in Azerbaijan.
To learn how Nexa Pharm can support your product registration and market access strategy, please contact our team.
